Clinical efficacy of fosinopril in hypertensive patients with metabolic disorders

Hypotensive effect of an angiotensin converting enzyme inhibitor fosinopril was investigated in 29 patients with stage II essential hypertension (hype rtensive disease) and metabolic disorders (excessive body mass, hypercholes terolemia and hyperinsulinemia). Effect of fosinopril on biochemical parame ters characterizing functional state of the kidney and liver were also stud ied. Fosinopril (10-20 mg/day) exerted stable hypotensive action in 89,6% o f patients without effect on initially normal biochemical parameters. Meanw hile significant lowering of plasma insulin level was observed what presuma bly reflected increased sensitivity of tissues to insulin. Thus in patients with essential hypertension hypotensive effect of fosinopril was not accom panied by worsening of function of elimination routes (liver and kidney) an d was associated with improvement of disturbed metabolic processes.